InvestorsHub Logo
Followers 20
Posts 1261
Boards Moderated 0
Alias Born 04/13/2013

Re: BAR123 post# 417170

Monday, 05/29/2023 7:53:22 AM

Monday, May 29, 2023 7:53:22 AM

Post# of 463574
What is beyond weird is biogen's past halting of aducanomab's (sp?) trial, then changing endpoints to reducing amyloid plaque and the FDA approval being based on that alone without consideration of the drug's efficacy.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News